Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 12391669
Substituted pyrimidines as IRE1 kinase inhibitors
granted -
US 12391654
CFTR regulators and methods of use thereof
granted -
US 12390483
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 12391643
Substituted amino-thiol and amino-disulfide compounds, and uses thereof
granted -
US 12390473
Methods of treating tyrosine kinase inhibitor-induced diarrhea
granted -
US 12391923
SIRPΞ±-silenced natural killer (NK) cells
granted -
US 12390427
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
granted -
US 12383627
Antimicrobial scaffolds
granted -
US 12383652
Nanofiber structures and methods of manufacture and use thereof
granted -
US 12383655
Methods of isolating and using descemet's membrane and compositions including isolated descemet's membrane
granted -
US 12384817
Peptide having protective activity against cell damage caused by particulate matter, and uses for same
granted -
US 12383518
Disulfide-masked pro-chelator compositions and methods of use
granted -
US 12385914
CRY1-clock-BMAL1 complex-disrupting agents and methods of identifying and using same
granted -
US 12384830
Compositions and methods for improving immunotherapy
granted -
US 12383499
Scale up synthesis of silicasome nanocarriers
granted -
US 12383629
DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2
granted -
US 12383534
Methods for treating cancer
granted -
US 12383538
Use of mTOR inhibitors for prevention of intestinal polyp growth and cancer
granted -
US 12384829
Pocket engineering of HLA alleles for treating autoimmunity
granted -
US 12377051
Microspheres for extended, controlled release of therapeutic agents
granted -
US 12377186
Antimicrobial biopolymer compositions, methods of synthesis, and applications of use
granted -
US 12377191
Chondroinductive peptides and compositions and methods of use thereof
granted -
US 12378193
Anti-arrhythmicity agents
granted -
US 12378337
Lipid nanodiscs solubilized through poly(acrylic acid-co-styrene) copolymers
granted -
US 12377069
Compounds, compositions, methods of using, and methods for preparing compounds
granted -
US 12378201
Histone demethylase inhibitors for treating cancers
granted -
US 12378286
Methods and compositions useful for inhibiting growth of certain bacteria
granted -
US 12370270
Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
granted -
US 12371466
Chimeric antigen receptor and methods of use thereof
granted -
US 12371499
Method of treating cancer using anti-AV8 antibodies
granted -
US 12371445
Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
granted -
US 12370256
Activation of resident memory T cells for the treatment of cancer
granted -
US 12364717
Compositions and methods for inhibiting seizures
granted -
US 12364736
Methods for treating heterotopic ossification
granted -
US 12365761
Biodegradable ultra-pH sensitive polymers
granted -
US 12365889
Tunable nanoscale cages from self-assembling DNA and protein building blocks
granted -
US 12364668
Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
granted -
US 12365875
Methods for generating skeletal muscle progenitor cells
granted -
US 12364609
Biomimetic implants
granted -
US 12365664
Small molecule inhibitors of SRC tyrosine kinase
granted -
US 12364688
NSD family inhibitors and methods of treatment therewith
granted -
US 12365693
Compositions and methods for treating cancer
granted -
US 12364661
Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
granted -
US 12365887
CRISPR-Cas effector polypeptides and methods of use thereof
granted -
US 12364765
Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria
granted -
US 12359204
Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer
granted -
US 12358971
Arena virus monoclonal antibodies and uses
granted -
US 12357617
Discovery of novel anti-infectives for gram negative pathogens
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory